The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs)
We performed this study to measure the Tumor Necrosis Factor-alpha (TNF-α) plasma level and to survey its correlation with disease activity in the newly diagnosed Rheumatoid Arthritis (RA) patients and those who were under treatment with the combination of Disease-Modifying Anti-Rheumatic Drug (DMAR...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2020-12-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100601&tlng=en |
| _version_ | 1818340320935411712 |
|---|---|
| author | Zahra Samimi Bahareh Kardideh Maryam Chalabi Parisa Zafari Mahdi Taghadosi |
| author_facet | Zahra Samimi Bahareh Kardideh Maryam Chalabi Parisa Zafari Mahdi Taghadosi |
| author_sort | Zahra Samimi |
| collection | DOAJ |
| description | We performed this study to measure the Tumor Necrosis Factor-alpha (TNF-α) plasma level and to survey its correlation with disease activity in the newly diagnosed Rheumatoid Arthritis (RA) patients and those who were under treatment with the combination of Disease-Modifying Anti-Rheumatic Drug (DMARD) plus Prednisolone (PSL).We enrolled 30 newly diagnosed RA patients who received no treatment regarding their disease, 30 patients under treatment with the combination of Methotrexate (MTX) + Hydroxychloroquine (HCQ) + PSL and 30 healthy subjects in this case-control study from September 2017 to December 2017. The level of plasma TNF-α was measured by enzyme-linked immunosorbent assay (ELISA) in each group. For assessment of disease severity, we used Disease Activity Score-28 (DAS-28) formula, and regarding DAS-28, we divided patients into four groups, including remission, low, moderate and high disease activity. There were no significant differences in the plasma level of TNF-α between the newly diagnosed RA patients and subjects who received MTX + HCQ + PSL, as well as healthy controls (p>0.05). There was a significant correlation between plasma levels of TNF-α and DAS-28 in the newly diagnosed patients with RA (r = 0.594, P = 0.001). Targeting TNF-α at the early stage of RA could have more beneficial effects on the amelioration of disease activity. |
| first_indexed | 2024-12-13T15:41:02Z |
| format | Article |
| id | doaj.art-ba30407d8992480f8e523431b75ee549 |
| institution | Directory Open Access Journal |
| issn | 2175-9790 |
| language | English |
| last_indexed | 2024-12-13T15:41:02Z |
| publishDate | 2020-12-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-ba30407d8992480f8e523431b75ee5492022-12-21T23:39:50ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902020-12-015610.1590/s2175-97902019000418551The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs)Zahra SamimiBahareh KardidehMaryam ChalabiParisa ZafariMahdi Taghadosihttps://orcid.org/0000-0002-3516-0130We performed this study to measure the Tumor Necrosis Factor-alpha (TNF-α) plasma level and to survey its correlation with disease activity in the newly diagnosed Rheumatoid Arthritis (RA) patients and those who were under treatment with the combination of Disease-Modifying Anti-Rheumatic Drug (DMARD) plus Prednisolone (PSL).We enrolled 30 newly diagnosed RA patients who received no treatment regarding their disease, 30 patients under treatment with the combination of Methotrexate (MTX) + Hydroxychloroquine (HCQ) + PSL and 30 healthy subjects in this case-control study from September 2017 to December 2017. The level of plasma TNF-α was measured by enzyme-linked immunosorbent assay (ELISA) in each group. For assessment of disease severity, we used Disease Activity Score-28 (DAS-28) formula, and regarding DAS-28, we divided patients into four groups, including remission, low, moderate and high disease activity. There were no significant differences in the plasma level of TNF-α between the newly diagnosed RA patients and subjects who received MTX + HCQ + PSL, as well as healthy controls (p>0.05). There was a significant correlation between plasma levels of TNF-α and DAS-28 in the newly diagnosed patients with RA (r = 0.594, P = 0.001). Targeting TNF-α at the early stage of RA could have more beneficial effects on the amelioration of disease activity.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100601&tlng=enRheumatoid arthritisTNF-αDAS-28DMARD |
| spellingShingle | Zahra Samimi Bahareh Kardideh Maryam Chalabi Parisa Zafari Mahdi Taghadosi The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs) Brazilian Journal of Pharmaceutical Sciences Rheumatoid arthritis TNF-α DAS-28 DMARD |
| title | The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs) |
| title_full | The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs) |
| title_fullStr | The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs) |
| title_full_unstemmed | The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs) |
| title_short | The plasma Tumor Necrosis Factor-α (TNF-α) does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti-rheumatic drugs (DMARDs) |
| title_sort | plasma tumor necrosis factor α tnf α does not have any correlation with disease activity in rheumatoid arthritis patients treated with disease modifying anti rheumatic drugs dmards |
| topic | Rheumatoid arthritis TNF-α DAS-28 DMARD |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100601&tlng=en |
| work_keys_str_mv | AT zahrasamimi theplasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT baharehkardideh theplasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT maryamchalabi theplasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT parisazafari theplasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT mahditaghadosi theplasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT zahrasamimi plasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT baharehkardideh plasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT maryamchalabi plasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT parisazafari plasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards AT mahditaghadosi plasmatumornecrosisfactoratnfadoesnothaveanycorrelationwithdiseaseactivityinrheumatoidarthritispatientstreatedwithdiseasemodifyingantirheumaticdrugsdmards |